Allspring Global Investments Holdings LLC Buys 29,465 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Allspring Global Investments Holdings LLC grew its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 16.3% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 210,531 shares of the company's stock after purchasing an additional 29,465 shares during the quarter. Allspring Global Investments Holdings LLC owned about 0.56% of Tarsus Pharmaceuticals worth $6,924,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in TARS. Quest Partners LLC acquired a new position in shares of Tarsus Pharmaceuticals in the 2nd quarter valued at $61,000. Canada Pension Plan Investment Board acquired a new position in shares of Tarsus Pharmaceuticals in the 2nd quarter valued at $114,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Tarsus Pharmaceuticals by 33.4% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company's stock valued at $166,000 after purchasing an additional 1,530 shares during the period. Dark Forest Capital Management LP acquired a new position in shares of Tarsus Pharmaceuticals in the 2nd quarter valued at $202,000. Finally, Bleakley Financial Group LLC acquired a new stake in Tarsus Pharmaceuticals during the 1st quarter worth $223,000. Institutional investors and hedge funds own 90.01% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on TARS. Oppenheimer reaffirmed an "outperform" rating and set a $63.00 price objective (up previously from $61.00) on shares of Tarsus Pharmaceuticals in a research note on Friday, August 9th. William Blair raised Tarsus Pharmaceuticals to a "strong-buy" rating in a research note on Friday, August 30th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Tarsus Pharmaceuticals has an average rating of "Buy" and an average price target of $51.60.

Tarsus Pharmaceuticals Stock Up 0.7 %

TARS stock traded up $0.26 during trading hours on Monday, reaching $39.67. 591,344 shares of the stock were exchanged, compared to its average volume of 700,149. The firm's 50-day moving average is $32.16 and its 200-day moving average is $31.21. The company has a market cap of $1.51 billion, a price-to-earnings ratio of -8.79 and a beta of 1.07. The company has a debt-to-equity ratio of 0.28, a current ratio of 7.03 and a quick ratio of 6.99. Tarsus Pharmaceuticals, Inc. has a 12 month low of $13.69 and a 12 month high of $42.50.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its earnings results on Thursday, August 8th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.98) by $0.10. The firm had revenue of $40.81 million during the quarter, compared to analysts' expectations of $31.30 million. Tarsus Pharmaceuticals had a negative return on equity of 63.99% and a negative net margin of 180.00%. During the same quarter in the prior year, the company earned ($1.17) EPS. On average, equities research analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.71 earnings per share for the current year.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.